Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Sanofi-Synthelabo

Penta Manufacturing Sanofi-Synthelabo Groupe (France)... [Pg.58]

Phone +33 1 53 77 40 00 E-mail Webmaster sanofi-synthelabo.com Web site www.sanofi-synthelabo.com Stock listing Paris Bourse 12057... [Pg.160]

Sanofi-Synthelabo researchers discovered pyrazole 53 and analogs to have potent Cannabinoid receptor-1 (CB-1) antagonist/inverse agonist activity and have progressed 53 into development for treatment of obesity and alcohol dependence. The synthesis of 53 was accomplished by heating the diketone sodium salt 51 with the aryl hydrazine hydrochloride in acetic acid to provide the intermediate 52, which was further derivatized... [Pg.297]

Plavix (Sanofi-Synthelabo USA Plavix (Sanofi Pharm ... [Pg.528]

Achour, Z., Laidboeur, T., Gien, O., Musolino, A., Bon, X., Grimaud, B. (2005) Sanofi-Synthelabo Chemical Development and the Development of an Electronic Laboratory Notebook. Organic Process Research Development, 8, 983-997. [Pg.227]

Sanofi-Synthelabo) has stimulated a great deal of interest in the diseovery of eannabinoid CBi reeeptor antagonists. This seetion aims to eover the strue-tures and therapeutie applieations of CBi antagonists published to date. Reviews of CBi reeeptor antagonists and their therapeutie applieations have recently appeared in the literature [260-262]. [Pg.273]

A close analogue of (385), the 4-hydroxypiperidine analogue (386) was recently described in a patent application from Sanofi-Synthelabo [271] and perhaps formed as a metabolite of the parent compound. [Pg.274]

Several studies have been reported on the application of conformational restraint to the 1,5-diaryl-pyrazole series in an attempt to provide compounds with modified properties. In one approach, a Sanofi-Synthelabo patent application claimed a series of conformationally restrained compounds, exemplified by compound (391). Compounds of the invention were stated to be CBi receptor antagonists with K[ values below 5 x 10 M and selectivity over CB2 receptors of at least 10-fold [274]. [Pg.276]

Conformationally restricted pyrazole-derived CB2 selective antagonists were described in a patent application from Sanofi-Synthelabo [384]. Compounds included in the application, exemplified by compound (609) are... [Pg.310]

Sanofi-Synthelabo believes a different formulation of the compound may also be effective in blocking the effects of cocaine. Under the tradename Rimonabant, Sanofi-Sythelabo is set to begin Phase 11 clinical trials aimed at determining whether SR141716 might also reduce the effects and desire for alcohol. ... [Pg.10]

Tablets 240 mg (equiv. to 200 mg tiludronic acid) Rx) Skelid (Sanofi-Synthelabo)... [Pg.356]

Tablets 75, 150, and 300 mg (Rx) Avapro (Bristol-Myers Squibb/Sanofi-Synthelabo)... [Pg.587]

Fasturtec (Elitex in USA) (rasburicase rUrate oxidase, Sanofi-Synthelabo Hyperuricaemia 2001 (EU), 2002 (USA)... [Pg.507]

Sanofi-Aventis ( 36 billion in sales). Headquartered in Paris, this company resulted from the takeover of Aventis in 2004 by Sanofi-Synthelabo. The company has strong sales in developing countries. [Pg.36]

Sanofi-Aventis is formed from the takeover of Aventis by Sanofi-Synthelabo. June 2 New York attorney general Eliot Spitzer sues the maker of Paxil, GlaxoSmithKline, for fraud in concealing the dangers of the drug for children under age 17 (the suit is settled when the company agrees to publish all its results). [Pg.113]

See other pages where Sanofi-Synthelabo is mentioned: [Pg.60]    [Pg.122]    [Pg.160]    [Pg.346]    [Pg.1335]    [Pg.265]    [Pg.273]    [Pg.357]    [Pg.455]    [Pg.458]    [Pg.465]    [Pg.465]    [Pg.465]    [Pg.465]    [Pg.465]    [Pg.537]    [Pg.470]    [Pg.95]    [Pg.224]    [Pg.230]    [Pg.10]    [Pg.16]    [Pg.373]    [Pg.834]    [Pg.834]    [Pg.1178]    [Pg.290]    [Pg.305]    [Pg.306]    [Pg.314]    [Pg.322]   
See also in sourсe #XX -- [ Pg.507 ]

See also in sourсe #XX -- [ Pg.36 , Pg.113 ]

See also in sourсe #XX -- [ Pg.32 , Pg.186 , Pg.240 ]

See also in sourсe #XX -- [ Pg.39 ]



SEARCH



Sanofi

© 2024 chempedia.info